Results 111 to 120 of about 78,435,061 (269)

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis   +4 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm   +2 more
wiley   +1 more source

18F-FDG-PET Imaging for Post-COVID-19 Brain and Skeletal Muscle Alterations

open access: yes, 2021
Scientific evidence concerning the subacute and long-term effects of coronavirus disease 2019 (COVID-19) is on the rise. It has been established that infection by serious acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a systemic process that ...
Laura L. Boles Ponto   +2 more
core   +1 more source

Dose‐related propofol resistance in COVID‐19 patients: Altered drug plasma levels, mechanistic insights from neuronal‐derived extracellular vesicles and miRNA analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Critical care for COVID‐19 patients presents unique challenges, particularly in sedation management. Patients demonstrate notable dose‐related resistance to propofol, potentially due to complex pharmacokinetic alterations. Emerging evidence suggests that plasma extracellular vesicle‐associated miRNA represents valuable predictive ...
Debora Curci   +10 more
wiley   +1 more source

Neurodivergence as a Risk Factor for Post-COVID-19 Syndrome [PDF]

open access: yes
Objectives: Neurodivergent (ND) individuals (e.g., autistic people) are more likely to experience health problems that are characterised by ‘Central Sensitisation’ (CS).
Raw, Rachael K.   +7 more
core   +1 more source

The Post-acute COVID-19 Syndrome (Long COVID)

open access: yesOman Medical Journal, 2021
Issa Al-Jahdhami   +2 more
openaire   +3 more sources

Insights into the Risk Factors and Outcomes of Post-COVID-19 Syndrome—Results from a Retrospective, Cross-Sectional Study in Romania

open access: yesLife
Post-Coronavirus Disease 2019 (post-COVID-19) syndrome represents a cluster of persistent symptoms following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection that can severely affect quality of life.
Ioana Bejan   +2 more
doaj   +1 more source

Benzodiazepines use in primary care England: Prescribing patterns and adverse consequences

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Benzodiazepines (BZDs) are commonly prescribed for anxiety and insomnia but carry risks such as dependence, adverse drug reactions (ADRs) and mortality. Despite deprescribing efforts, the influence of recent prescribing trends, COVID‐19 and adverse outcomes on prescribing patterns in England remains uncertain.
Alvina Chaudhry   +3 more
wiley   +1 more source

Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich   +24 more
wiley   +1 more source

Safety of proton pump inhibitors in children: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To systematically evaluate the safety of proton pump inhibitor (PPI) therapy in children aged 0–12 years, with a focus on treatment‐emergent adverse events across different study designs and age groups. Method The systematic review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA ...
Ahmad Raza Sachel   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy